- Autor
-
Pracoviště
Brain and Mind Centre University of S... 1 Center for Neuroinflammation and Expe... 1 Department of Neurology Medical Facul... 1 Department of Neurology Medical Unive... 1 Department of Neurology Palacký Unive... 1 Department of Neurology and Neurologi... 1 Weill Institute for Neurosciences Dep... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
-
Pracoviště
Brain and Mind Centre University of S... 1 Center for Neuroinflammation and Expe... 1 Department of Neurology Medical Facul... 1 Department of Neurology Medical Unive... 1 Department of Neurology Palacký Unive... 1 Department of Neurology and Neurologi... 1 Weill Institute for Neurosciences Dep... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Hartung, Hans-Peter
Autor Hartung, Hans-Peter Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia Department of Neurology, Medical University of Vienna, Vienna, Austria Department of Neurology, Palacký University Olomouc, Olomouc, Czechia
- Cree, Bruce A C
- Barnett, Michael
- Meuth, Sven G
- Bar-Or, Amit
- Steinman, Lawrence
Free Medical Journals od 2010
PubMed Central od 2010
Europe PubMed Central od 2010
Open Access Digital Library od 2010-01-01
Open Access Digital Library od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources od 2010
PubMed
38162670
DOI
10.3389/fimmu.2023.1290666
Knihovny.cz E-zdroje
Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous system play a critical role. To our knowledge, alemtuzumab, fumarates (dimethyl, diroximel, and monomethyl), glatiramer acetates, interferons, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, and teriflunomide are either limited to the periphery or insufficiently studied to confirm direct central nervous system effects in participants with multiple sclerosis. In contrast, cladribine and sphingosine 1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are central nervous system-penetrant and could have beneficial direct central nervous system properties.
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.